| Literature DB >> 30679813 |
Sandra Jansen1, Ilse M van der Werf2, A Micheil Innes3, Alexandra Afenjar4,5, Pankaj B Agrawal6, Ilse J Anderson7, Paldeep S Atwal8, Ellen van Binsbergen9, Marie-José van den Boogaard9, Lucia Castiglia10, Zeynep H Coban-Akdemir11,12, Anke van Dijck2, Diane Doummar13,14,15, Albertien M van Eerde9, Anthonie J van Essen16, Koen L van Gassen9, Maria J Guillen Sacoto17, Mieke M van Haelst18, Ivan Iossifov19,20, Jessica L Jackson8, Elizabeth Judd21, Charu Kaiwar22,23, Boris Keren24, Eric W Klee25, Jolien S Klein Wassink-Ruiter16, Marije E Meuwissen2, Kristin G Monaghan17, Sonja A de Munnik1, Caroline Nava24,26, Charlotte W Ockeloen1, Rosa Pettinato27, Hilary Racher3,28, Tuula Rinne1, Corrado Romano27, Victoria R Sanders29, Rhonda E Schnur17, Eric J Smeets30, Alexander P A Stegmann30, Asbjørg Stray-Pedersen11,31,32, David A Sweetser33, Paulien A Terhal9, Kristian Tveten34, Grace E VanNoy6, Petra F de Vries1, Jessica L Waxler33, Marcia Willing35, Rolph Pfundt1, Joris A Veltman1,36, R Frank Kooy2, Lisenka E L M Vissers1, Bert B A de Vries37.
Abstract
Determining pathogenicity of genomic variation identified by next-generation sequencing techniques can be supported by recurrent disruptive variants in the same gene in phenotypically similar individuals. However, interpretation of novel variants in a specific gene in individuals with mild-moderate intellectual disability (ID) without recognizable syndromic features can be challenging and reverse phenotyping is often required. We describe 24 individuals with a de novo disease-causing variant in, or partial deletion of, the F-box only protein 11 gene (FBXO11, also known as VIT1 and PRMT9). FBXO11 is part of the SCF (SKP1-cullin-F-box) complex, a multi-protein E3 ubiquitin-ligase complex catalyzing the ubiquitination of proteins destined for proteasomal degradation. Twenty-two variants were identified by next-generation sequencing, comprising 2 in-frame deletions, 11 missense variants, 1 canonical splice site variant, and 8 nonsense or frameshift variants leading to a truncated protein or degraded transcript. The remaining two variants were identified by array-comparative genomic hybridization and consisted of a partial deletion of FBXO11. All individuals had borderline to severe ID and behavioral problems (autism spectrum disorder, attention-deficit/hyperactivity disorder, anxiety, aggression) were observed in most of them. The most relevant common facial features included a thin upper lip and a broad prominent space between the paramedian peaks of the upper lip. Other features were hypotonia and hyperlaxity of the joints. We show that de novo variants in FBXO11 cause a syndromic form of ID. The current series show the power of reverse phenotyping in the interpretation of novel genetic variances in individuals who initially did not appear to have a clear recognizable phenotype.Entities:
Mesh:
Substances:
Year: 2019 PMID: 30679813 PMCID: PMC6462006 DOI: 10.1038/s41431-018-0292-2
Source DB: PubMed Journal: Eur J Hum Genet ISSN: 1018-4813 Impact factor: 4.246